Rossari Biotech Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹697Cr
- +28.1% YoY
- +1.8% QoQ
- Net profit
- ₹35Cr
- +2.9% YoY
- −23.9% QoQ
- Margin
- 12%
- 0 pp YoY
- +1 pp QoQ
Guidance rank: #45 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
FY27 revenue growth guidance is around 15%, despite Q1 showing a strong 28% growth (Page 7, 13). Rossari targets over 15% top-line growth annually, as reiterated for FY27 despite current global uncertainties.
From Rossari Biotech Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- FY27 revenue growth guidance is around 15%, despite Q1 showing a strong 28% growth (Page 7, 13).
- Growth driven by ramp-up in utilization of new capacity and new products from recent expansions (Page 7).
- Volume growth in Q1 was about 10%, with the remainder of top-line growth from price increases (Page 12).
- Increased EO capacity expected by end of FY27 to drive healthy growth in FY27 and FY28 (Pages 12, 13).
- New product introductions like vitamin premixes, enzymes, esters, and pharma segment to support volume expansion (Pages 11, 12).
2 more points from Rossari Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX in India has slowed down; only calibrated spending on new CAPEX is planned, focusing on new products/molecules such as pharma and aroma chemicals.
- No large CAPEX planned for this year; focus is on utilizing existing capacities efficiently.
- Early-stage operational and exploratory expenses have begun for the Saudi Arabia (KSA) greenfield project, despite the West Asia geopolitical situation.
- The KSA project remains a key strategic initiative, with active engagement with partners, suppliers, consultants, and the Saudi ministry; plans include setting up downstream EO and non-EO products.
- Expected gestation for KSA production start is around 1.5 years from investment announcement.
2 more points from Rossari Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Rossari Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Rossari Biotech Ltd — Quarterly revenue & net profit
Rossari Biotech Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 697 | 544 | +28.1% | 685 | +1.8% |
| Operating profit (EBITDA) | 81 | 68 | +19.1% | 77 | +5.2% |
| Operating margin | 12% | 12% | 0 pp | 11% | +1 pp |
| Profit before tax | 48 | 46 | +4.3% | 64 | -25% |
| Net profit (PAT) | 35 | 34 | +2.9% | 46 | -23.9% |
| EPS (₹) | 6.34 | 6.07 | +4.4% | 8.30 | -23.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rossari Biotech's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Alufluoride (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
- POCL Enterprises (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
- Devson Catalyst (Q1 FY27)
FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee
- Ambani Orgochem (Q1 FY27)
Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rossari Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rossari Biotech Ltd Q1 FY27 results?
FY27 revenue growth guidance is around 15%, despite Q1 showing a strong 28% growth (Page 7, 13). Rossari targets over 15% top-line growth annually, as reiterated for FY27 despite current global uncertainties.
What is Rossari Biotech Ltd share price analysis?
Rossari Biotech Ltd currently shows a below-average growth signal. The stock trades at a P/E of 16.1 with a market cap of ₹2,426 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rossari Biotech Ltd planning capital expenditure?
Current CAPEX in India has slowed down; only calibrated spending on new CAPEX is planned, focusing on new products/molecules such as pharma and aroma chemicals.
Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
